Growth stocks in focus: can buying CRISPR Therapeutics at $50 make me rich?

Dr James Fox takes a closer look at one of the most promising growth stocks, CRISPR Therapeutics. Could this gene-editing stock make him rich?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

CRISPR Therapeutics (NASDAQ:CRSP) is possibly the most speculative growth stock I’m buying for my portfolio. It’s not traditionally something that would interest me, but the more I read, the more interested I became.

So, at $50, can CRISPR Therapeutics make me rich?

Gene therapy prospects

CRISPR Therapeutics is a speculative pick as governments and regulators round the world have been hesitant to back gene therapy treatments. 

CRISPR, an acronym for ‘clustered regularly interspaced short palindromic repeats’, refers to a gene-editing technology utilised by the firm.

Despite initial hesitancy, this is a highly promising therapy that is increasingly demonstrating its efficacy, and CRISPR Therapeutics is not the only company validating the promise of this technology.

Attitudes to the tech are seemingly changing, and even over the last year, we’ve seen increasing confidence that these treatments, dependent on efficacy, will receive regulatory approval.

But there is of course risk here. CRISPR treatments are not proven over the long run yet.

Near-term wins

The market has struggled to value CRISPR Therapeutics, despite progress on the firm’s sickle cell disease (SCD) approval. The treatment could be approved this year.

The stock traded for over $190 a share back in January 2021 after the company had just received a $900m upfront payment from its partner Vertex.

But conversely, as CRISPR Therapeutics gets closer to monetising the treatment, the stock trades for just $50.

Other gene-editing firms are also developing SCD treatments, but CRISPR Therapeutics’ Exa-Cel treatment appears to have a very strong chance of being the first-ever approved CRISPR-based therapy.

This would be a blockbuster moment for the firm. In trials, Exa-Cel demonstrated impressive efficacy. Of 44 patients, 42 were “functionally cured” of their disease. However, it is worth noting that long-term durability has not been established — only time will tell.

Being the first CRISPR treatment on the market could generate billions in revenue. Calculations suggest the treatment could cost $1m per patient during their lives — less than existing treatments — and that 32,000 people would be eligible at first. This creates a $32bn market opportunity.

The product could be launched this year. It is worth noting that Vertex would receive more than half the revenue generated.

Strong pipeline

Biotech can be a volatile part of the market. CRISPR Therapeutics is currently trading near its three-year low, but just one piece of positive trial data could send the share price soaring.

Overall, the firm’s pipeline includes 25 programmes. With initial data suggesting CRISPR therapies have a wide range of applications, this a reason to get excited about the long-term prospects of this stock. CRISPR Therapeutics also has $2bn in cash to aid development.

Source: CRISPR Therapeutics presentation

The firm also has two additional oncology therapies that could become marketed products in the next couple of years.

CTX-110 targets a protein — CD19 — present in B-cell malignancies such as large B-cell lymphoma. Meanwhile, CTX130 targets a protein called CD70 in the treatment of T-cell lymphomas, including certain solid tumours.

There’s no guarantee these treatments will receive regulatory approval. However, it is a highly promising part of the market and one that could deliver millions of positive health outcomes in the future. That’s why I’m adding this stock to my portfolio.

Can it make me rich if I put $5,000 in at $50? Well, I certainly hope so. Considering the pure size of the SCD opportunity, I think it could be undervalued on this alone.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has no position in any of the shares mentioned. The Motley Fool UK has recommended CRISPR Therapeutics. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »